Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 29:12:693009.
doi: 10.3389/fphar.2021.693009. eCollection 2021.

Real-World Effectiveness of Adjuvant Oxaliplatin Chemotherapy in Stage III Colon Cancer: A Controlled Interrupted Time Series Analysis

Wen-Kuan Huang  1   2   3 , Hung-Chih Hsu  1   2 , Shu-Hao Chang  4 , Wen-Chi Chou  1   2 , Pei-Hung Chang  2   5 , Sum-Fu Chiang  6 , John Wen-Cheng Chang  1   2 , Jen-Shi Chen  1   2 , Tsai-Sheng Yang  1   2 , Lai-Chu See  4   7   8
Affiliations

Real-World Effectiveness of Adjuvant Oxaliplatin Chemotherapy in Stage III Colon Cancer: A Controlled Interrupted Time Series Analysis

Wen-Kuan Huang et al. Front Pharmacol. .

Abstract

Background: The real-world effectiveness of oxaliplatin in stage III colon cancer has not been determined in a large-scale population. We aimed to assess the real-world impact of adjuvant oxaliplatin treatment on the survival of these patients. Methods: Based on Taiwan cancer registry, we evaluated 17,801 patients with resected stage III colon cancer, including 14,168 patients receiving adjuvant chemotherapy and 3,633 not receiving adjuvant chemotherapy as the control group between 2004 and 2014. We used the controlled interrupted time-series analysis to assess the three-year disease-free survival and five-year overall survival rates before (2004-2008) and after (2009-2014) the addition of oxaliplatin. Results: The introduction of oxaliplatin was associated with no significant improvement in the slopes (per half-year) of the three-year disease-free survival rate (0.2%, 95% CI: -1.7∼2.2%) and five-year overall survival rate (0.6%, 95% CI: -1.8∼3%). The patients receiving oxaliplatin-based chemotherapy also showed no significant increase in the slopes (per half-year) of the three-year disease-free survival rate (0.6%, 95% CI: -1.4∼2.6%) and five-year overall survival rate (1%, 95% CI: -1.5∼3.5%). The nonsignificant results were consistent across subgroup analyses of age (<70 vs. ≥70 years), recurrence risk (T1-3 or N1 vs. T4 or N2), and cycle of oxaliplatin use (≤6 vs. >6). However, oxaliplatin-based chemotherapy significantly increased the slope (per half-year) of the five-year OS (2%, 95% CI: 0.2∼3.8%) for patients in the high-risk group (T4 or N2). The present results were robust in several sensitivity analyses. Conclusion: Among real-world patients with stage III colon cancer, the introduction of oxaliplatin does not yield a significant improvement in survival. Future work should identify the subpopulation(s) of patients who benefit significantly from the addition of oxaliplatin.

Keywords: adjuvant chemotherapy; interrupted time series study; mortality; oxaliplatin; stage III colorectal cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Survival outcomes by calendar year before and after oxaliplatin reimbursement in the entire population. (A) Three-year DFS rates for overall cohorts, (B) Five-year OS rates for overall cohorts, (C) Three-year DFS rates for oxaliplatin cohort, (D) Five-year OS rates for oxaliplatin cohort. The vertical broken lines delineate the intervention time [between quarter 4 (Q4) 2008 and Q1 2009]. DFS: disease-free survival; OS: overall survival.
FIGURE 2
FIGURE 2
Forest plot of the regression coefficients for the CITS for the overall cohort and for the oxaliplatin cohort. Please refer to eMethod 1 in the Supplement for explanation of the regression coefficients (β 2 –β 7).
FIGURE 3
FIGURE 3
Forest plot of the regression coefficients for the CITS for the overall cohort and for the oxaliplatin cohort with subgroups: aged <70 years; aged ≥70 years; T1-3 and N1; T4 or N2; ≤ 6 oxaliplatin cycles; >6 oxaliplatin cycles. Please refer to the eMethod 1 in the Supplement for the explanation of the regression coefficients (β 6 , β7).
FIGURE 4
FIGURE 4
Forest plot of the regression coefficients for the CITS for the overall cohort and for the oxaliplatin cohort with sensitivity analyses: no prior cancer history, excluding one-year transition period, excluding biweekly fluoropyrimidine treatment before the intervention. Please refer to eMethod 1 in the Supplement for explanation of the regression coefficients (β 6 , β 7).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. André T., Boni C., Navarro M., Tabernero J., Hickish T., Topham C., et al. (2009). Improved Overall Survival with Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment in Stage II or III colon Cancer in the MOSAIC Trial. Jco 27, 3109–3116. 10.1200/JCO.2008.20.6771 - DOI - PubMed
    1. André T., De Gramont A., Vernerey D., Chibaudel B., Bonnetain F., Tijeras-Raballand A., et al. (2015). Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study. Jco 33, 4176–4187. 10.1200/JCO.2015.63.4238 - DOI - PubMed
    1. Anglemyer A., Horvath H. T., Bero L. (2014). Healthcare Outcomes Assessed with Observational Study Designs Compared with Those Assessed in Randomized Trials. Cochrane Database Syst. Rev., MR000034. 10.1002/14651858.MR000034.pub2 - DOI - PMC - PubMed
    1. Arnold M., Sierra M. S., Laversanne M., Soerjomataram I., Jemal A., Bray F. (2017). Global Patterns and Trends in Colorectal Cancer Incidence and Mortality. Gut 66, 683–691. 10.1136/gutjnl-2015-310912 - DOI - PubMed
    1. Batra A., Kong S., Cheung W. Y. (2020). Eligibility of Real-World Patients with Stage II and III Colon Cancer for Adjuvant Chemotherapy Trials. Clin. Colorectal Cancer 19, e226–e234. 10.1016/j.clcc.2020.05.005 - DOI - PubMed

LinkOut - more resources